Cargando…
A standardised framework to identify optimal animal models for efficacy assessment in drug development
INTRODUCTION: Poor translation of efficacy data derived from animal models can lead to clinical trials unlikely to benefit patients–or even put them at risk–and is a potential contributor to costly and unnecessary attrition in drug development. OBJECTIVES: To develop a tool to assess, validate and c...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563989/ https://www.ncbi.nlm.nih.gov/pubmed/31194784 http://dx.doi.org/10.1371/journal.pone.0218014 |
_version_ | 1783426632940257280 |
---|---|
author | S. Ferreira, Guilherme Veening-Griffioen, Désirée H. Boon, Wouter P. C. Moors, Ellen H. M. Gispen-de Wied, Christine C. Schellekens, Huub van Meer, Peter J. K. |
author_facet | S. Ferreira, Guilherme Veening-Griffioen, Désirée H. Boon, Wouter P. C. Moors, Ellen H. M. Gispen-de Wied, Christine C. Schellekens, Huub van Meer, Peter J. K. |
author_sort | S. Ferreira, Guilherme |
collection | PubMed |
description | INTRODUCTION: Poor translation of efficacy data derived from animal models can lead to clinical trials unlikely to benefit patients–or even put them at risk–and is a potential contributor to costly and unnecessary attrition in drug development. OBJECTIVES: To develop a tool to assess, validate and compare the clinical translatability of animal models used for the preliminary assessment of efficacy. DESIGN AND RESULTS: We performed a scoping review to identify the key aspects used to validate animal models. Eight domains (Epidemiology, Symptomatology and Natural History–SNH, Genetic, Biochemistry, Aetiology, Histology, Pharmacology and Endpoints) were identified. We drafted questions to evaluate the different facets of human disease simulation. We designed the Framework to Identify Models of Disease (FIMD) to include standardised instructions, a weighting and scoring system to compare models as well as factors to help interpret model similarity and evidence uncertainty. We also added a reporting quality and risk of bias assessment of drug intervention studies in the Pharmacological Validation domain. A web-based survey was conducted with experts from different stakeholders to gather input on the framework. We conducted a pilot study of the validation in two models for Type 2 Diabetes (T2D)–the ZDF rat and db/db mouse. Finally, we present a full validation and comparison of two animal models for Duchenne Muscular Dystrophy (DMD): the mdx mouse and GRMD dog. We show that there are significant differences between the mdx mouse and the GRMD dog, the latter mimicking the human epidemiological, SNH, and histological aspects to a greater extent than the mouse despite the overall lack of published data. CONCLUSIONS: FIMD facilitates drug development by serving as the basis to select the most relevant model that can provide meaningful data and is more likely to generate translatable results to progress drug candidates to the clinic. |
format | Online Article Text |
id | pubmed-6563989 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-65639892019-06-20 A standardised framework to identify optimal animal models for efficacy assessment in drug development S. Ferreira, Guilherme Veening-Griffioen, Désirée H. Boon, Wouter P. C. Moors, Ellen H. M. Gispen-de Wied, Christine C. Schellekens, Huub van Meer, Peter J. K. PLoS One Research Article INTRODUCTION: Poor translation of efficacy data derived from animal models can lead to clinical trials unlikely to benefit patients–or even put them at risk–and is a potential contributor to costly and unnecessary attrition in drug development. OBJECTIVES: To develop a tool to assess, validate and compare the clinical translatability of animal models used for the preliminary assessment of efficacy. DESIGN AND RESULTS: We performed a scoping review to identify the key aspects used to validate animal models. Eight domains (Epidemiology, Symptomatology and Natural History–SNH, Genetic, Biochemistry, Aetiology, Histology, Pharmacology and Endpoints) were identified. We drafted questions to evaluate the different facets of human disease simulation. We designed the Framework to Identify Models of Disease (FIMD) to include standardised instructions, a weighting and scoring system to compare models as well as factors to help interpret model similarity and evidence uncertainty. We also added a reporting quality and risk of bias assessment of drug intervention studies in the Pharmacological Validation domain. A web-based survey was conducted with experts from different stakeholders to gather input on the framework. We conducted a pilot study of the validation in two models for Type 2 Diabetes (T2D)–the ZDF rat and db/db mouse. Finally, we present a full validation and comparison of two animal models for Duchenne Muscular Dystrophy (DMD): the mdx mouse and GRMD dog. We show that there are significant differences between the mdx mouse and the GRMD dog, the latter mimicking the human epidemiological, SNH, and histological aspects to a greater extent than the mouse despite the overall lack of published data. CONCLUSIONS: FIMD facilitates drug development by serving as the basis to select the most relevant model that can provide meaningful data and is more likely to generate translatable results to progress drug candidates to the clinic. Public Library of Science 2019-06-13 /pmc/articles/PMC6563989/ /pubmed/31194784 http://dx.doi.org/10.1371/journal.pone.0218014 Text en © 2019 S. Ferreira et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article S. Ferreira, Guilherme Veening-Griffioen, Désirée H. Boon, Wouter P. C. Moors, Ellen H. M. Gispen-de Wied, Christine C. Schellekens, Huub van Meer, Peter J. K. A standardised framework to identify optimal animal models for efficacy assessment in drug development |
title | A standardised framework to identify optimal animal models for efficacy assessment in drug development |
title_full | A standardised framework to identify optimal animal models for efficacy assessment in drug development |
title_fullStr | A standardised framework to identify optimal animal models for efficacy assessment in drug development |
title_full_unstemmed | A standardised framework to identify optimal animal models for efficacy assessment in drug development |
title_short | A standardised framework to identify optimal animal models for efficacy assessment in drug development |
title_sort | standardised framework to identify optimal animal models for efficacy assessment in drug development |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563989/ https://www.ncbi.nlm.nih.gov/pubmed/31194784 http://dx.doi.org/10.1371/journal.pone.0218014 |
work_keys_str_mv | AT sferreiraguilherme astandardisedframeworktoidentifyoptimalanimalmodelsforefficacyassessmentindrugdevelopment AT veeninggriffioendesireeh astandardisedframeworktoidentifyoptimalanimalmodelsforefficacyassessmentindrugdevelopment AT boonwouterpc astandardisedframeworktoidentifyoptimalanimalmodelsforefficacyassessmentindrugdevelopment AT moorsellenhm astandardisedframeworktoidentifyoptimalanimalmodelsforefficacyassessmentindrugdevelopment AT gispendewiedchristinec astandardisedframeworktoidentifyoptimalanimalmodelsforefficacyassessmentindrugdevelopment AT schellekenshuub astandardisedframeworktoidentifyoptimalanimalmodelsforefficacyassessmentindrugdevelopment AT vanmeerpeterjk astandardisedframeworktoidentifyoptimalanimalmodelsforefficacyassessmentindrugdevelopment AT sferreiraguilherme standardisedframeworktoidentifyoptimalanimalmodelsforefficacyassessmentindrugdevelopment AT veeninggriffioendesireeh standardisedframeworktoidentifyoptimalanimalmodelsforefficacyassessmentindrugdevelopment AT boonwouterpc standardisedframeworktoidentifyoptimalanimalmodelsforefficacyassessmentindrugdevelopment AT moorsellenhm standardisedframeworktoidentifyoptimalanimalmodelsforefficacyassessmentindrugdevelopment AT gispendewiedchristinec standardisedframeworktoidentifyoptimalanimalmodelsforefficacyassessmentindrugdevelopment AT schellekenshuub standardisedframeworktoidentifyoptimalanimalmodelsforefficacyassessmentindrugdevelopment AT vanmeerpeterjk standardisedframeworktoidentifyoptimalanimalmodelsforefficacyassessmentindrugdevelopment |